Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2020.

Pharming’s CEO Sijmen de Vries and Leon Melens look back at the first half year and the recently published half year financial results.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, the proposals related to remuneration were withdrawn and all other proposals were approved.

Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.

Pharming Group N.V. today supports “hae-day :-)”, the global awareness day for hereditary angioedema (HAE), a rare life-threatening condition.

Pharming Group N.V. holds it 2020 Annual General Meeting (AGM) on 20 May 2020 at 14:00 CET.

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020.

Pharming Group N.V. announces that it has received formal European Commission approval to treat acute hereditary angioedema (HAE) attacks in children with RUCONEST®. Following the positive opinion and recommendation from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the extension of the indication for RUCONEST® received on 26 March 2020.

Pharming Group N.V. announces encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.